Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.994E-12 | 1.582E-08 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP2, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.289E-07 | 1.559E-04 | CYP2C19, CYP2C9, CYP2D6 |
MF | GO:0005215; transporter activity | GO:0005329; dopamine transmembrane transporter activity | 1.289E-07 | 1.559E-04 | SLC22A1, SLC22A2, SLC22A3 |
BP | GO:0051179; localization | GO:0006855; drug transmembrane transport | 1.368E-07 | 1.568E-04 | SLC22A1, SLC22A2, SLC22A3, SLC47A1, SLC47A2 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.070E-07 | 5.105E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6 |
MF | GO:0005215; transporter activity | GO:0015651; quaternary ammonium group transmembrane transporter activity | 5.392E-07 | 5.105E-04 | SLC22A1, SLC22A2, SLC22A3 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.496E-31 | 3.258E-27 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015872; dopamine transport | 1.407E-06 | 1.094E-03 | SLC22A1, SLC22A2, SLC22A3 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.407E-06 | 1.094E-03 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0051179; localization | GO:0015697; quaternary ammonium group transport | 1.407E-06 | 1.094E-03 | SLC22A1, SLC22A2, SLC22A3 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.319E-06 | 2.766E-03 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0051179; localization | GO:0072488; ammonium transmembrane transport | 5.176E-06 | 3.220E-03 | SLC22A1, SLC22A2, SLC22A3 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.403E-06 | 4.945E-03 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.070E-05 | 5.417E-03 | CA2, CA7 |
MF | GO:0005215; transporter activity | GO:0015307; drug:proton antiporter activity | 1.070E-05 | 5.417E-03 | SLC47A1, SLC47A2 |
MF | GO:0005215; transporter activity | GO:0005333; norepinephrine transmembrane transporter activity | 1.070E-05 | 5.417E-03 | SLC22A1, SLC22A2 |
MF | GO:0005215; transporter activity | GO:0005277; acetylcholine transmembrane transporter activity | 1.070E-05 | 5.417E-03 | SLC22A1, SLC22A2 |
MF | GO:0005215; transporter activity | GO:0008513; secondary active organic cation transmembrane transporter activity | 1.070E-05 | 5.417E-03 | SLC22A1, SLC22A2 |
BP | GO:0051179; localization | GO:0015874; norepinephrine transport | 2.137E-05 | 9.694E-03 | SLC22A1, SLC22A2 |
BP | GO:0051179; localization | GO:1901374; acetate ester transport | 2.137E-05 | 9.694E-03 | SLC22A1, SLC22A2 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.699E-24 | 7.294E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.428E-22 | 7.771E-19 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.337E-30 | 1.444E-28 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.862E-06 | 4.246E-04 | CYP2C9; CYP2A6; CYP2D6; CYP2C19 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.919E-05 | 2.131E-03 | MMP2; MMP9; TP53 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.764E-04 | 9.260E-03 | PAX8; MMP2; TP53; MMP9; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.316E-04 | 7.177E-03 | CYP2C9; CYP2A6; CYP2D6 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.323E-04 | 7.177E-03 | PAX8; TP53; MMP9; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 8.090E-04 | 9.260E-03 | MMP2; MMP9; ESR2 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.574E-04 | 9.260E-03 | SLC22A3; SLC22A2; SLC22A1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.668E-04 | 8.402E-03 | CYP2C9; CYP2A6; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.156E-03 | 1.088E-02 | CYP2C9; CYP2D6; CYP2C19 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.191E-03 | 1.578E-02 | LMNA; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.018E-03 | 1.557E-02 | RAB9A; TP53; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.469E-03 | 1.666E-02 | TP53; MMP9; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.211E-03 | 3.511E-02 | MMP2; TP53; MMP9 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.221E-04 | 9.260E-03 | CA2; CA4 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.310E-03 | 1.088E-02 | PAX8; TP53 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.873E-03 | 3.511E-02 | CYP2C9; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.310E-03 | 1.088E-02 | CYP2C9; CYP2C19 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.631E-03 | 3.511E-02 | TP53; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.437E-03 | 3.511E-02 | CYP2C9; CYP2A6 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.827E-03 | 3.511E-02 | HKDC1; TP53 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.846E-03 | 3.626E-02 | NFKB1; ESR2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.058E-03 | 3.626E-02 | TP53; NFKB1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.179E-02 | 4.546E-02 | TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.637E-03 | 3.626E-02 | CA2; SLC22A1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.104E-02 | 4.416E-02 | TP53; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.308E-02 | 4.871E-02 | TP53; NFKB1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.217E-03 | 3.828E-02 | CYP2A6 |
hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 9.217E-03 | 3.828E-02 | HKDC1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; MMP9; MMP2 |
NA: NA | Upper abdominal bloating | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | MC4R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia nervosa cachexia | F50.0-F50.1 | MC4R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | MC4R |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | MC4R |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | MC4R; MC4R; MC4R; MC4R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | MC4R |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | MC4R |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | MC4R; MC4R; MC4R |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; CA9; MMP9; NFKB1; ACHE; MMP2 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |